RECURSION PHARMACEUTICALS-A (RXRX) Stock Analyst Ratings
USA - NASDAQ:RXRX - US75629V1044 - Common Stock
5.52 USD
-0.13 (-2.3%)
5.51 USD
-0.01 (-0.18%)
ChartMill assigns a Buy % Consensus number of 73% to RXRX. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 6.6. This target is 19.49% above the current price.
RXRX was analyzed by 14 analysts. The buy percentage consensus is at 73. So analysts seem to be have mildly positive about RXRX.
In the previous month the buy percentage consensus was at a similar level.
RXRX was analyzed by 14 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-09-11 | Needham | Reiterate | Buy -> Buy |
| 2025-07-08 | Needham | Reiterate | Buy -> Buy |
| 2025-06-16 | Morgan Stanley | Maintains | Equal-Weight -> Equal-Weight |
| 2025-05-06 | Needham | Maintains | Buy -> Buy |
| 2025-04-10 | Morgan Stanley | Maintains | Equal-Weight -> Equal-Weight |
| 2025-04-08 | Needham | Reiterate | Buy -> Buy |
| 2025-02-28 | Leerink Partners | Maintains | Market Perform -> Market Perform |
| 2025-02-06 | Needham | Reiterate | Buy -> Buy |
| 2025-01-08 | Keybanc | Maintains | Overweight -> Overweight |
| 2024-12-11 | Needham | Reiterate | Buy -> Buy |
| 2024-11-20 | Needham | Reiterate | Buy -> Buy |
| 2024-11-07 | Needham | Reiterate | Buy -> Buy |
| 2024-09-04 | Needham | Maintains | Buy -> Buy |
| 2024-09-03 | Leerink Partners | Maintains | Market Perform -> Market Perform |
| 2024-09-03 | Jefferies | Maintains | Hold -> Hold |
| 2024-08-09 | Needham | Maintains | Buy -> Buy |
| 2024-07-11 | Keybanc | Maintains | Overweight -> Overweight |
| 2024-06-25 | Needham | Reiterate | Buy -> Buy |
| 2024-05-10 | Needham | Reiterate | Buy -> Buy |
| 2024-04-09 | Needham | Reiterate | Buy -> Buy |
| 2024-03-04 | Keybanc | Maintains | Overweight -> Overweight |
| 2024-02-28 | Needham | Maintains | Buy -> Buy |
| 2024-01-26 | TD Cowen | Initiate | Market Perform |
| 2024-01-17 | Needham | Reiterate | Buy -> Buy |
| 2024-01-16 | Needham | Reiterate | Buy -> Buy |
| 2023-11-13 | JP Morgan | Maintains | Neutral -> Neutral |
| 2023-11-09 | Needham | Maintains | Buy -> Buy |
| 2023-09-05 | Needham | Reiterate | Buy -> Buy |
| 2023-08-09 | Needham | Reiterate | Buy -> Buy |
| 2023-07-21 | Needham | Reiterate | Buy -> Buy |
RECURSION PHARMACEUTICALS-A / RXRX FAQ
What is the average price target for RECURSION PHARMACEUTICALS-A (RXRX) stock?
14 analysts have analysed RXRX and the average price target is 6.6 USD. This implies a price increase of 19.49% is expected in the next year compared to the current price of 5.52.
How do analysts rate RECURSION PHARMACEUTICALS-A (RXRX)?
The consensus rating for RECURSION PHARMACEUTICALS-A (RXRX) is 72.8571 / 100 . This indicates that analysts generally have a positive outlook on the stock.
How many analysts cover RECURSION PHARMACEUTICALS-A (RXRX) stock?
The number of analysts covering RECURSION PHARMACEUTICALS-A (RXRX) is 14.